Share this article
CENTENNIAL, Colo., Feb. 23, 2021 /PRNewswire/
AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products, today announced the first patients have been enrolled in its clinical study titled,
A Randomized, Controlled Study to
Evaluate Effectiveness of AlloWrap® Amniotic Membrane for the Reduction of Post-Operative Soft Tissue Inflammation in Two-Level Anterior Cervical Discectomy and Fusion (ACDF) Procedures.
There are an estimated 300,000 ACDF procedures performed annually in the United States. Despite the overall positive outcomes of these procedures, one potentially costly and painful complication is inflammation of the surrounding tissue, which can cause painful swallowing and/or loss of language. The primary objective of this study is to obtain evidence of the effectiveness of AlloWrap Amniotic Membrane in the reduction of soft tissue swelling in two-level ACDF procedures.